breakingview - astrazeneca’s messag warrant a review, too
london (reuter breakingview) - astrazeneca’s vaccin home run is in danger of turn into a curvebal. the $134 billion drug giant is plan to review it covid-19 vaccin candid to clarifi how effect it is. while it’s do so, the uk group should probabl do a separ review of how it commun.
